Sera PrognosticsSERA -2.17%70 Net Margin % is -59,992.86% as of Mar. 2026. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 99.63% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sera Prognostics's Net Income for the
three
months ended in Mar. 2026 was $-8.40 Mil. Sera Prognostics's Revenue for the
three
months ended in Mar. 2026 was $0.01 Mil. Therefore, Sera Prognostics's net margin for the quarter that ended in Mar. 2026 was -59,992.86%.
The historical rank and industry rank for Sera Prognostics's Net Margin % or its related term are showing as below:
SERA'
s Net Margin % Range Over the Past 10 Years
Min: -79392 Med: -42693.9 Max: -11843.79
Current: -56385.97
SERA's Net Margin % is ranked worse than 99.63% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs SERA: -56385.97
Sera Prognostics (NAS:SERA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sera Prognostics Net Margin % Related Terms
Sera Prognostics Net Margin % Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sera Prognostics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a Net Margin % of -59,992.86% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #814 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 99.6%.
Is Sera Prognostics' Net Margin % too high?
Sera Prognostics' current Net Margin % is -59,992.86%. Based on the distribution chart, Sera Prognostics ranks #814 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Net Margin % compare to ECOR and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #814 out of 817 companies for Net Margin %. This places Sera Prognostics in the lower half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current Net Margin % is -59,992.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Fairly Valued. The stock's GF Value™ is $1.86, compared to a current price of $1.84 — trading 1.1% below its estimated fair value. The current Net Margin % is -59,992.86%. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Net Margin % is -59,992.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be undervalued.
The current stock price of $1.84 is trading 1.1% below its estimated GF Value™ of $1.86.
GuruFocus considers Sera Prognostics to be Fairly Valued.
Key valuation signals for SERA:
Net Margin %: -59,992.86%
GF Value™: $1.86 vs. price of $1.84 (1.1% below fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score
Get the complete analysis for SERA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
